2022
November
Two is better than one: combining bispecific antibodies for signal 1 and signal 2
November 30, 2022
Patients with diffuse large B cell lymphoma (DLBCL) are given rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone as a first-line treatment, and while this therapy is quite effective, 30-40% of patients are refractory or relapse, and face a poor prognosis with second- and third-line treatments. Although some bispecific T cell engagers that provide “signal...
SITC Annual Meeting 2022
November 23, 2022
This week’s extensive special feature covers select talks from the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, MA and virtually. We are proud to recognize Takeda for sponsorship of our coverage for this conference.We have organized the content by topics below.Keynote addressPadmanee SharmaBig dataHanna CarterNir HacohenBenjamin D...
Targeting the sialoglycan-Siglec axis for cancer immunotherapy
November 16, 2022
In cancer, upregulation of sialic acid-containing glycans (hypersialylation) is a feature that has been shown to drive disease progression and immune escape through engagement with Siglec receptors and inhibition of tumor-infiltrating immune cells. In previous work, Stanczak et al. showed that genetic desialylation or treatment with sialidase could reduce tumor growth and contribute...
Not all routes lead to Rome: administration route affects vaccine responses
November 9, 2022
Since cytolytic T cells are critical to cancer immunotherapy, therapeutic cancer vaccines, which can induce such T cells, can be an important component of immunotherapy. However, current vaccine approaches to improve the magnitude of the immune response have traditionally shown limited antitumor effects. Taking a new approach, Baharom, Ramirez-Valdez, Khalilnezhad, et al. evaluated...
AACR Tumor Immunology and Immunotherapy Meeting 2022
November 2, 2022
Last week, the ACIR team attended the AACR Tumor Immunology and Immunotherapy Meeting 2022 in Boston, MA. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. T cell therapiesEric TranMelody SmithRobbie MajznerTumor microenvironmentZev A. WainbergGarry P. NolanZihai LiShannon J. TurleyAmy MoranMyeloid cellsJennifer L...
